Login
Companies $ICCC
$11.64 +$0.22 (1.93%) Pre-market
IMMUCELL CORP logo

IMMUCELL CORP

immucell.com

What Do They Do?

Sells antibody-based calf scours preventives and on-farm milk tests to dairy and beef producers.

How Do They Make Money?

Dairy and beef producers are reached through distributors; ImmuCell sells products to distributors and invoices when products ship, with customers paying against those invoices.

revenue
SegmentShareRevenue
Corporate Segment, Scours
Sold outright

99%
Corporate Segment, Mastitis
Sold outright
0.7%

Who Are Their Customers?

The company promotes its products to veterinarians and dairy and beef producers, then sells mainly through animal-health distributors, which supply veterinary clinics, fleet stores and farms.

Do Revenues Turn Into Profits?

Not on paper. It lost $1M in FY2025, but brought in more cash than it spent: $1.2M of free cash flow.

Operating income, FY2025
6% of revenue
▲ Turned profitable vs FY2024 (−$1.6M, −6%)
Net income, FY2025
−4% of revenue
▲ +52% (Loss) vs FY2024 (−$2.2M, −8%)
Free cash flow, FY2025
4% of revenue
▲ Turned profitable vs FY2024 (−$107.8K, 0%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +46%
vs $5.5M in Q3 FY2025
Net income
▲ Turned profitable
vs −$139.7K in Q3 FY2025
Corporate Segment, Scours share of revenue vs 98.9% in Q3 FY2025

Re-Tain's role The older report described completing Re-Tain's manufacturing work to pursue FDA approval alongside First Defense. The latest report says the company has stopped pursuing in-house manufacturing, redirected related facilities to First Defense, and may seek a licensee or partner for Re-Tain.

Who Do They Compete With?

Competes with Zoetis, Elanco, Merck, Boehringer Ingelheim, and CEVA

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support